Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4972.

https://doi.org/10.1182/blood-2023-189844

Published: 2023

Journal Articles

A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-142680

Published: 2020

Journal Articles

Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma.

Qaiser Bashir, Peter Thall, Chitra Hosing, Floralyn L Mendoza, Eric Han, Michael Wang, M.D., Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, Partow Kebriaei, Issa F. Khouri, Uday Popat, MD, Marcos de Lima, MD, Richard Champlin, MD, Sergio A Giralt, MD, Muzaffar H Qazilbash

Blood (2009) 114 (22): 1186.

https://doi.org/10.1182/blood.V114.22.1186.1186

Published: 2009

Journal Articles

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Manish Sharma, MD, Peter Thall, PhD, Xuemei Wang, PhD, Chitra Hosing, MD, Floralyn L Mendoza, MD, Eric Han, MD, Michael Wang, MD, Donna Weber, MD, Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, MD, Partow Kebriaei, MD, Issa F Khouri, MD, Uday Popat, MD, Marcos de Lima, MD, Richard E Champlin, MD, Sergio Giralt, MD, Muzaffar Qazilbash, MD

Blood (2009) 114 (22): 2309.

https://doi.org/10.1182/blood.V114.22.2309.2309

Published: 2009

Journal Articles

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies.

Partow Kebriaei, MD, Timothy Madden, BS, PHARMD, Reza Kazerooni, RPH, Elizabeth Shpall, MD, Xuemei Wang, MS, Peter Thall, MD, Chitra Hosing, MD, Muzaffar Qazilbash, MD, Uday Popat, MD, Celina Ledesma, BS, Issa Khouri, MD, Richard Champlin, MD, Roy Jones, MD, Borje S. Andersson, MD

Blood (2009) 114 (22): 3415.

https://doi.org/10.1182/blood.V114.22.3415.3415

Published: 2009

Journal Articles

Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.

Marcos De Lima, Leandro de Padua Silva, Sergio Giralt, Krishna Komanduri, Borje S. Andersson, Chitra Hosing, Muzaffar Qazilbash, Elizabeth Shpall, Peter Thall, Weiqing Zhang, Gloria McCormick, Xuemei Wang, Uday Popat, Andres Soriano, Amin Alousi, Richard Champlin, Guillermo Garcia-Manero

Blood (2008) 112 (11): 1134.

https://doi.org/10.1182/blood.V112.11.1134.1134

Published: 2008

Journal Articles

Phase 1 Clinical Study of Adoptive Immunotherapy with Delayed Infusion of Alloanergized Donor T Cells to Improve Immune Reconstution after Haploidentical Stem Cell Transplantation.

Jeff Davies, Marcos De Lima, Laurence Cooper, Thomas Spitzer, Neena Kapoor, Lisa Brennan, Peter Thall, John McMannis, Richard Champlin, Lee Nadler, Eva Guinan

Blood (2008) 112 (11): 1156.

https://doi.org/10.1182/blood.V112.11.1156.1156

Published: 2008

Journal Articles

Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study

Blood (2008) 112 (11): 154.

https://doi.org/10.1182/blood.V112.11.154.154

Published: 2008

Journal Articles

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Paul M. Armistead, MD, PhD, Marcos de Lima, MD, Sherry Pierce, RN, Wei Qiao, PhD, Xuemei Wang, PhD, Peter Thall, PhD, Sergio Giralt, MD, Richard Champlin, MD, Elihu Estey, MD

Blood (2007) 110 (11): 329.

https://doi.org/10.1182/blood.V110.11.329.329

Published: 2007

Journal Articles

Manipulation of Oxygen Tension and Medium Composition To Enhance CD34+ Cell Numbers and Megakaryocytic Potential of Cord Blood Progenitors.

Shannon M. Kidd, BS, Nathalie Brouard, Ph.D., Kevin Cao, Simon N. Robinson, Ph.D., Michael Thomas, MS, Tuongvan Nguyen, BS, Wei Qiao, MS, Peter Thall, Ph.D., Patrick Zweidler-McKay, MD, Ph.D., Elizabeth J. Shpall, MD, Paul J. Simmons, Ph.D.

Blood (2007) 110 (11): 772.

https://doi.org/10.1182/blood.V110.11.772.772

Published: 2007

Journal Articles

Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.

Andres O. Soriano, MD, Richard Champlin, MD, Gloria McCormick, Sergio Giralt, MD, Peter Thall, PhD, Krishna Komanduri, MD, Muzaffar Qazilbash, MD, Guillermo Garcia-Manero, MD, Marcos De Lima, MD

Blood (2006) 108 (11): 3668.

https://doi.org/10.1182/blood.V108.11.3668.3668

Published: 2006

Journal Articles

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Daniel R. Couriel, MD, Peter Thall, PhD, Kerry Mickler, RN, Marcos De Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, Chitra Hosing, MD, Issa Khouri, MD, Partow Kebriaei, MD, Yvonne Hsu, MD, Rima Saliba, MD, Cindy Ippoliti, PharmD, Richard Champlin, MD

Blood (2005) 106 (11): 142.

https://doi.org/10.1182/blood.V106.11.142.142

Published: 2005

Journal Articles

Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.

Muzaffar H. Qazilbash, MD, Eric Wieder, PhD, Rosa Rios, Sijie Lu, Shreya Kant, Sergio Giralt, MD, Elihu H. Estey, MD, Peter Thall, Marcos de Lima, MD, Daniel Couriel, MD, Richard E. Champlin, MD, Krishna Komanduri, MD, Jeffrey J. Molldrem, MD

Blood (2004) 104 (11): 259.

https://doi.org/10.1182/blood.V104.11.259.259

Published: 2004

Journal Articles

Plausibility of Delaying Induction Therapy in Untreated AML.

Elihu H. Estey, MD, X.-M. Wang, MS, Peter Thall, PhD, Sherry Pierce, BSN, Charles Koller, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Hagop Kantarjian, MD

Blood (2004) 104 (11): 879.

https://doi.org/10.1182/blood.V104.11.879.879

Published: 2004

Journal Articles

Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy

Elihu Estey, Peter Thall, Miloslav Beran, Hagop Kantarjian, Sherry Pierce, Michael Keating

Blood (1997) 90 (8): 2969–2977.

https://doi.org/10.1182/blood.V90.8.2969

Published: 1997

NARROW

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS

Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma.

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies.

Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.

Phase 1 Clinical Study of Adoptive Immunotherapy with Delayed Infusion of Alloanergized Donor T Cells to Improve Immune Reconstution after Haploidentical Stem Cell Transplantation.

Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Manipulation of Oxygen Tension and Medium Composition To Enhance CD34+ Cell Numbers and Megakaryocytic Potential of Cord Blood Progenitors.

Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.

Plausibility of Delaying Induction Therapy in Untreated AML.

Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only